ArticleClinical and vaccine immunology : CVI2008
Evaluation of the recombinant VlsE-based liaison chemiluminescence immunoassay for detection of Borrelia burgdorferi and diagnosis of Lyme disease.
Article in Clinical and vaccine immunology : CVI, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- The Accuracy of Diagnostic Tests for Lyme Disease in Humans, A Systematic Review and Meta-Analysis of North American Research.PloS one · 2016Pooled it
- Cerebrospinal Fluid Profiles Across Clinical Manifestations of Early European Lyme Neuroborreliosis.Open forum infectious diseases · 2026Article
- Comparison of the Serodiagnostic Accuracy Tests for Lyme Disease in Adults and Children: A Network Meta-Analysis.Pathogens (Basel, Switzerland) · 2025Review
- First Detection of Seroreactivity to Lyme Borreliosis in Agricultural Workers from a Non-Endemic Region of South Korea.Yonsei medical journal · 2025Article
- Performance of two modified two-tier algorithms for the serologic diagnosis of Lyme disease.Journal of clinical microbiology · 2024Article
- Neuroborreliosis and Post-Treatment Lyme Disease Syndrome: Focus on Children.Life (Basel, Switzerland) · 2023Article
- Immunoreactivity of Polish Lyme Disease Patient Sera to SpecificDiagnostics (Basel, Switzerland) · 2021Article
- Laboratory Diagnosis of Lyme Borreliosis.Clinical microbiology reviews · 2021Review
- Optimizing use of multi-antibody assays for Lyme disease diagnosis: A bioinformatic approach.PloS one · 2021Article
- Quantitative serological antibody testing for suspected neuroborreliosis.Journal of neurology · 2020Article
- Multicenter Evaluation of the C6 Lyme ELISA Kit for the Diagnosis of Lyme Disease.Microorganisms · 2020Article
- Emerging Tick-Borne Diseases.Clinical microbiology reviews · 2020Review
- Immunoserological Diagnosis of Human Borrelioses: Current Knowledge and Perspectives.Frontiers in cellular and infection microbiology · 2020Review
- Antibodies to Borrelia turicatae in Experimentally Infected Dogs Cross-React with Borrelia burgdorferi Serologic Assays.Journal of clinical microbiology · 2019Article
- The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.BMC public health · 2019Article
- Evaluation of a Novel Microarray Immunoblot Assay for Detection of IgM- and IgG-Class Antibodies to Borrelia burgdorferi.Journal of clinical microbiology · 2018Article
- Recent strategies for the diagnosis of early Lyme disease.Science progress · 2018Review
- Evaluation of Modified Two-Tiered Testing Algorithms for Lyme Disease Laboratory Diagnosis Using Well-Characterized Serum Samples.Journal of clinical microbiology · 2018Article
- A Community Study ofHealthcare (Basel, Switzerland) · 2018Article
- Advances in Serodiagnostic Testing for Lyme Disease Are at Hand.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent efforts to improve the serologic diagnosis of Lyme disease have included the use of a synthetic peptide (C6) that reproduces the sequence of invariable region 6 of VlsE, the variable surface antigen of Borrelia burgdorferi. In the present study, the diagnostic performance of DiaSorin's recombinant VlsE-based chemiluminescence immunoassay in 1,947 human serum samples was evaluated. Sensitivity was determined using two serum panels from the CDC. For panel I, we observed sensitivities of 68.4% and 75.6% for subjects with early, localized (n=19) or disseminated (n=41) disease, respectively. For panel II, we observed sensitivities of 61.5% and 100% for subjects with early (n=26) or late-stage (n=11) disease, respectively. We observed a specificity of 99.5% for healthy donors (n=600) living either in regions of the United States where the disease is endemic or in regions where it is not endemic. Overall, specificity among 207 potentially cross-reactive sera from subjects who had other spirochetal infections, nonspirochetal infections including bacterial and viral infections, or autoimmune or neurologic disease; who were positive for rheumatoid factor or anti-mouse antibodies; or who had been previously vaccinated for Lyme disease was 93.7%. In a direct comparison of 1,038 prospectively collected samples for Lyme disease testing we observed a relative sensitivity of 70%, a relative specificity of 99.1%, and an overall agreement of 97.1% between the DiaSorin recombinant VlsE chemiluminescence immunoassay and the Immunetics peptide-based C6 enzyme-linked immunosorbent assay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.